Your browser doesn't support javascript.
loading
Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
Otte, Maximillian; Dauben, Hans Peter; Ahn, Jeonghoon; Gutierrez Ibarluzea, Iñaki; Drummond, Michael; Simoens, Steven; Kaló, Zoltán; Suh, Dong-Churl.
Afiliación
  • Otte M; OITBpathway V. o. G, Eupen, Belgium.
  • Dauben HP; OITBpathway V. o. G, Eupen, Belgium.
  • Ahn J; Department of Health Convergence, Ewha Womans University, Seoul, South Korea.
  • Gutierrez Ibarluzea I; Health ClusterNET, Amsterdam, Netherlands.
  • Drummond M; Centre for Health Economics, University of York, York, UK.
  • Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Kaló Z; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Suh DC; Syreon Research Institute, Budapest, Hungary.
Expert Rev Pharmacoecon Outcomes Res ; : 1-6, 2024 Sep 02.
Article en En | MEDLINE | ID: mdl-39221874
ABSTRACT

INTRODUCTION:

This paper summarizes the results from a forum of healthcare experts, academia representatives, and public agency officials from emerging and established market countries on Value-Based Healthcare (VBHC) and Health Technology Assessment (HTA). Presentations from experts provided insights into current developments and challenges, followed by interactive roundtable discussions. Emerging markets have unique healthcare systems, patient populations, resource constraints and needs. AREAS COVERED Each roundtable explored specific topics including the role of HTA and Real-world evidence (RWE) in healthcare decision-making, challenges in biosimilar value assessment and incorporating non-price criteria reflecting context-related specifications of emerging markets such as the multifaceted nature of value in healthcare decision-making, emphasizing stakeholder perspectives and system complexities. EXPERT OPINION RWE emerged as important in understanding biosimilar value recognition and decision-making processes, with insights into its applications and challenges. Recommendations were provided for utilizing Multi-Criteria Decision Analysis (MCDA) in pharmaceutical procurement, particularly for off-patent medicines, underscoring the importance of comprehensive evaluation frameworks and adherence to value-based principles. Overall findings suggest avenues for collaboration between industry, academia, and public agencies to address implementation barriers and promote equitable, efficient, and high-quality healthcare systems in emerging markets through public-private partnerships, joint capacity building and training initiatives, and knowledge transfers.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido